Seer, Inc.
NASDAQ:SEER · NASDAQ Global Select
+$0.01 today
Vol 0.08M · Avg 0.32M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SEER · Revenue to Net Income
Key Ratios
Analysis
$15.0M of revenue converted into -$70.5M of net income for the selected period. Gross margin is 47.2% and net margin is -479.4%, showing how much revenue survives after costs and taxes. EPS is $-1.24, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.1M +15.6% | $13.9M -8.1% | $15.2M +3.4% | $14.7M +129.7% | $6.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $14.2M +99.8% | $7.1M -48.2% | $13.7M -4.0% | $14.3M +111.3% | $6.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.9M -72.2% | $6.8M +371.5% | $1.4M +277.3% | $384.0K +202.7% | -$374.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 11.8% -37.2pp | 49.0% +39.4pp | 9.5% +6.9pp | 2.6% +8.5pp | -5.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $37.8M -25.3% | $50.6M +6.6% | $47.4M +3.6% | $45.8M +57.3% | $29.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $42.6M -24.7% | $56.6M -4.0% | $59.0M +12.0% | $52.6M +24.7% | $42.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $80.4M -24.9% | $106.9M +0.5% | $106.4M +8.1% | $98.4M +38.0% | $71.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.1M -1.2% | $6.2M +10.7% | $5.6M -5.5% | $5.9M +65.6% | $3.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$67.3M +16.2% | -$80.3M +0.5% | -$80.7M +7.3% | -$87.1M -28.8% | -$67.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -417.5% +158.4pp | -575.9% -44.4pp | -531.5% +61.3pp | -592.9% +464.5pp | -1057.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$78.5M +21.6% | -$100.1M +4.6% | -$104.9M -7.0% | -$98.0M -36.7% | -$71.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -486.7% +231.0pp | -717.7% -26.5pp | -691.2% -23.6pp | -667.6% +453.7pp | -1121.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.5M -30.9% | $16.7M -6.2% | $17.8M +286.0% | $4.6M +1311.7% | $326.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 -100.0% | $22.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $5.1M -62.9% | $13.6M -27.1% | $18.7M +267.6% | $5.1M +863.4% | $527.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$73.4M +15.1% | -$86.5M -0.3% | -$86.3M +7.2% | -$93.0M -30.6% | -$71.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -455.4% +164.9pp | -620.2% -51.9pp | -568.3% +64.8pp | -633.1% +480.0pp | -1113.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $201.0K +105.1% | $98.0K | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$73.6M +15.0% | -$86.6M -0.4% | -$86.3M +7.2% | -$93.0M -30.6% | -$71.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -456.6% +164.3pp | -620.9% -52.6pp | -568.3% +64.8pp | -633.1% +480.0pp | -1113.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +7.9% | -$1 -3.0% | -$1 +4.9% | -$1 -25.7% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +7.9% | -$1 -3.0% | -$1 +4.9% | -$1 -25.7% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $57.4M -7.9% | $62.3M -2.4% | $63.9M +2.3% | $62.4M +2.6% | $60.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $57.4M -7.9% | $62.3M -2.4% | $63.9M +2.3% | $62.4M +2.6% | $60.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.40B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.65B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.48B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.18B
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$943.77M
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$894.39M
Sana Biotechnology, Inc.
NASDAQ:SANA
$869.66M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$335.86M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$294.24M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$242.78M
Shattuck Labs, Inc.
NASDAQ:STTK
$231.97M
Quantum-Si incorporated
NASDAQ:QSI
$196.42M
Nkarta, Inc.
NASDAQ:NKTX
$194.67M
Molecular Partners AG
NASDAQ:MOLN
$147.61M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$136.19M
PepGen Inc.
NASDAQ:PEPG
$124.28M
MediciNova, Inc.
NASDAQ:MNOV
$65.22M
Generation Bio Co.
GBIO
$35.98M
Anebulo Pharmaceuticals, Inc.
ANEB
$17.23M
HCW Biologics Inc.
HCWB
$2.21M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SEER generate?
Seer, Inc. (SEER) reported $16.12M of revenue in fiscal 2025.
Is SEER profitable?
Seer, Inc. (SEER) reported -$73,600,000.00 of net income, with a net margin of -456.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.